Accelerator Platforms

Start your development project with our accelerator platform services, designed to speed up phase I clinical trial readiness and derisk development approaches.

Get ready with our In Silico Assessment, Formulatability Assessment and Preformulation Screening platform services for a variety of modalities (therapeutic proteins and peptides). Drawing from our extensive scientific expertise, we have designed these service platforms to help our clients determine the ideal strategy right from the start while keeping an eye on potential stage-related risks.

In Silico Assessment

The in silico service provides a powerful starting point for formulation and drug product development. By combining advanced computational tools with deep biologics expertise, we help you make informed decisions early, saving time, cost, and material.

- Early risk mitigation
- Integrated validation
- End-to-end support
- Data-driven decisions
- Resource efficiency
- Descriptor benchmarking
- Machine learning
- Molecular dynamics simulations

Developability and Formulatability Assessment

Reduce time to market and costs while mitigating risk for your program with our streamlined and innovative Developability and Formulatability approach. Select the most promising candidates with the most favorable biophysical properties as a foundation for successful drug product development, accelerating time to market.

The Developability and Formulatability Assessment service package includes:

- High throughput, low sample consumption methods for candidate screening
- Wet-lab assessment in one matrix
- Optional benchmarking to commercial drug products
- In-depth characterization with dedicated methods to determine self-interactions and predict risk at high concentration
- Supported by in silico analysis with machine learning and molecular dynamics simulation
- Assessment in two matrices
- Benchmarking to commercial drug products
- Application of our full advanced method set for predicting stability and the influence of the formulation
- Supported by in silico analysis with machine learning and molecular dynamics simulation
- Assessment in four matrices
- Benchmarking to commercial drug products

Preformulation Screening

Go from molecule to formulation within six weeks with our preformulation screening service. Systematically screen a vast formulation space, including only excipients accepted for parenteral application, and comprehensively generate holistic drug product development data, including accelerated stability and forced degradation readouts. This approach allows for the careful selection of lead formulations for subsequent stability studies and further preclinical drug product development for your program.

- Preparation of 80 formulation variants
- Conformational stability
- Colloidal stability
- Chemical stability
- Protein–protein interaction
- Basic characterization
- Standardized data analysis and visualization
- Focused design of experiments (DoE) evaluation
- Result interpretation from Coriolis experts
- Heat maps for formulation selection

We’ve worked with over 930 modalities, and the number is growing by the day.

Your Drug Product

Coriolis Pharma’s deep expertise across many biologic modalities, combined with input from world-leading external advisors, offers the knowledge and experience needed to solve even the most complex formulation and drug development challenges.

Antibody or Related Product

Peptide

Therapeutic Protein

Gene & Cell Therapy

Viral Vector

Nucleic Acid

Vaccine

Nanoparticulate Delivery Systems

Your Phase

Our expert team has the knowledge and experience to guide your program from discovery to preclinical drug development, through clinical phases and to the market.

Preclinical

Early Phase

Late Phase & Commercialization

Commercial Services

Coriolis Effect

See how our expertise and comprehensive services accelerate biologics development from preclinical to the market.